By efrat|2024-09-16T08:56:30+00:00September 16th, 2024|All|Comments Off on September 20th 2024- Prof. Qian Jiang- A Predictive Model for Therapy Failure in CML Patients Receiving Tyrosine Kinase Inhibitor Therapy
By efrat|2024-09-12T08:55:26+00:00September 12th, 2024|All|Comments Off on September 13th 2024- Prof. Martin Ellis- Differential Effects of Itacitinib, Fedratinib, and Ruxolitinib in Mouse Models of Hemophagocytic Lymphohistiocytosis
By efrat|2024-08-28T12:19:56+00:00September 1st, 2024|All|Comments Off on September 2nd 2024- Prof. Mark Litzow- Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults
By efrat|2024-08-06T08:16:01+00:00August 25th, 2024|All|Comments Off on August 26th 2024- Prof. Olaf Penack- How risky is a second allogeneic stem cell transplantation?
By efrat|2024-07-16T12:38:00+00:00July 20th, 2024|All|Comments Off on July 22nd 2024- Dr. Kai Rejeski- A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy
By efrat|2024-07-16T06:49:04+00:00July 16th, 2024|All|Comments Off on July 16th 2024- Prof. Madhav Dhodapkar- Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
By efrat|2024-07-04T15:03:17+00:00July 4th, 2024|All|Comments Off on July 7th 2024- Dr. Anand Patel- Treatment approach and outcomes of patients with accelerated/blast-phase myeloproliferative neoplasms in the current era
By efrat|2024-06-16T07:59:45+00:00June 23rd, 2024|All|Comments Off on June 24th 2024- Dr. Tamar Tadmor- Supplement of Vitamin D for early-stage Chronic Lymphocytic Leukemia Patients is Associated with a Longer Time to first Treatment
By efrat|2024-06-16T07:54:57+00:00June 16th, 2024|All|Comments Off on June 17th 2024- Prof. Saad Usmani- Antigen Escape as a Shared Mechanism of Resistance to BCMA-Directed Therapies in Multiple Myeloma
By efrat|2024-06-06T10:12:14+00:00June 10th, 2024|All|Comments Off on June 11th 2024- Dr. Zachariah DeFilipp- Flares of Acute Graft-Versus-Host Disease: a Mount Sinai Acute GVHD International Consortium Analysis
